Nanjing Medical University

XuehaoWang_VFThe Hepatobiliary Center at the First Affiliated Hospital of Nanjing Medical University is a leading research-focused medical center that specializes in precision treatments for liver cancer and LDLT. A trailblazer in international liver cancer interventional therapy, the center made a groundbreaking contribution in 1987 by being the first to combine 125I iodized oil with chemotherapy drugs, effectively integrating radiotherapy, chemotherapy, and embolization for treating intermediate and advanced liver cancer. This institution played a pivotal role in performing mainland China's first LDLT, significantly advancing the practice in the nation. It is also recognized for initiating neoadjuvant targeted immunotherapy for liver cancer, with its pioneering clinical research published in the Journal for Immunotherapy of Cancer. Moreover, the center developed the Chinese Expert Consensus on Neoadjuvant Therapy for Liver Cancer. It maintains a long-standing commitment to both basic and clinical research in liver cancer and transplantation. This dedication is evidenced by over 600 papers published in prestigious journals, including Cell Metabolism, Cancer Discovery, Journal of Hepatology, Gut, Nature Communications, Hepatology, and Science Translational Medicine.